<DOC>
	<DOCNO>NCT00595374</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare efficacy safety insulin detemir insulin NPH adult type 1 diabetes blood glucose control .</brief_summary>
	<brief_title>Efficacy Safety Insulin Detemir Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Duration type 1 diabetes least 12 month BMI 35 kg/m2 HbA1c 7.012.0 % Current treatment preprandial short act insulin insulin NPH twice daily least 6 month Fertile female must use acceptable method contraception risk pregnancy opinion Investigator Known suspect allergy trial product relate product Previous participation trial Receipt investigational product within last 2 month prior trial Drug alcohol dependence Pregnancy , breastfeed intention become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>